Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 13:4:10.
doi: 10.1038/s41536-019-0073-8. eCollection 2019.

Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research

Marion T Turnbull  1 , Abba C Zubair  2 , James F Meschia  3 , William D Freeman  3   4   5
Affiliations
Review

Mesenchymal stem cells for hemorrhagic stroke: status of preclinical and clinical research

Marion T Turnbull et al. NPJ Regen Med. .

Abstract

Significant progress has been made during the past few decades in stem cell therapy research for various diseases and injury states; however this has not been overwhelmingly translated into approved therapies, despite much public attention and the rise in unregulated 'regenerative clinics'. In the last decade, preclinical research focusing on mesenchymal stem/stromal cell (MSC) therapy in experimental animal models of hemorrhagic stroke has gained momentum and has led to the development of a small number of human trials. Here we review the current studies focusing on MSC therapy for hemorrhagic stroke in an effort to summarize the status of preclinical and clinical research. Preliminary evidence indicates that MSCs are both safe and tolerable in patients, however future randomized controlled trials are required to translate the promising preclinical research into an effective therapy for hopeful patients.

Keywords: Mesenchymal stem cells; Stroke.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Roadmap of preclinical studies
See this image and copyright information in PMC

References

    1. Sipp D. The malignant niche: safe spaces for toxic stem cell marketing. npj Regen. Med. 2017;2:33. doi: 10.1038/s41536-017-0036-x. - DOI - PMC - PubMed
    1. European Medicines Agency. Alofisel, https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel (2018).
    1. Yang Q, et al. Vital signs: recent trends in stroke death rates-United States, 2000–2015. Mmwr. Morb. Mortal. Wkly. Rep. 2017;66:933–939. doi: 10.15585/mmwr.mm6635e1. - DOI - PMC - PubMed
    1. Freeman WD, Brott TG. Modern treatment options for intracerebral hemorrhage. Curr. Treat. options Neurol. 2006;8:145–157. doi: 10.1007/s11940-006-0005-y. - DOI - PubMed
    1. Hackett ML, Anderson CS, Group, A. C. R. o. S. H. S. Health outcomes 1 year after subarachnoid hemorrhage an international population-based study. Neurology. 2000;55:658–662. doi: 10.1212/WNL.55.5.658. - DOI - PubMed